WELCOME TO CTX PLATFORMS
TRANSLATING AEONS OF EVOLUTION TO CURRENT CLINICAL PRACTICE
A MULTI-MODAL CONTRAST AGENT FOR CANCER IMAGING AND HYPERTHERMIA
This novel contrast media agent is developed to support preoperative planning, assess clinical response, and enable staging using MRI or CT.
Giving it's selective affinity to various cancers and BBB penetrative abilities, it is also designed to enable magnetic hyperthermia (alternating magnetic- fields induced tumor ablation).
NANO-PARTICLE BASED IMAGING
Viable tumor mapping is well needed in clinical oncology since CTs and Gd-supported MRI's are not necessarily showing a living cancer tissue (as in post-treatment necrosis or inflammation). The solution we develop is applicable both in MRIs as well as CTs.
This cutting edge technology offers neurosurgeons a non-intrusive tumor ablation solution for recurrent gliomas as well as tumor resections in hard to reach areas in the CNS.
CTX Platforms Ltd is a biotechnology company that was founded in 2018 and is located at Be'er Sheva Science Park, in Southern Israel.
The company is rapidly advancing towards a disruptive targeted technology application for imaging and treatment of brain cancers and other non-CNS tumors.
The technology uses supra-magnetic nanoparticles to effectively visualize living tumors, as well as to treat them with magnetic hyperthermia.
CTX develops its proprietary particles under license from cutting edge technology and academic centers.
The company is currently raising round-A investment in order to complete preclinical trials for imaging and treatment of GBM.
CTX Platforms is supported by the Israeli Innovation Authority and has advanced in the POC stage in-vitro.
For more information about our work, email us and we will be happy to share our enthusiasm with you.
Meet our shared-dream makers